35306-75-3

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Bromo-N-isopropylbenzamide is used as an intermediate in the synthesis of various pharmaceuticals, including nonsteroidal anti-inflammatory drugs (NSAIDs) and anticancer agents. Its chemical structure allows for the development of drugs that target inflammation and cancer cells, providing a foundation for the creation of effective therapeutics.
Used in Organic Chemistry:
In the field of organic chemistry, 3-Bromo-N-isopropylbenzamide is utilized for the synthesis of diverse heterocyclic compounds. Its reactivity and structural features make it a versatile building block for the preparation of complex organic molecules with potential applications in various chemical and pharmaceutical processes.
Used in Drug Development:
3-Bromo-N-isopropylbenzamide is studied for its potential therapeutic applications, showing promise in the development of new pharmaceuticals. Its unique properties and reactivity contribute to the advancement of drug discovery, offering a platform for the design and synthesis of innovative biologically active compounds with potential therapeutic benefits.

InChI:InChI=1/C10H12BrNO/c1-7(2)12-10(13)8-4-3-5-9(11)6-8/h3-7H,1-2H3,(H,12,13)

Upstream product

• 35309-72-9 N,N-diisopropyl-3-bromobenzamide 
• 1711-09-7 3-bromobenzoyl chloride 
• 75-31-0 isopropylamine 

Downstream Products

• 65261-74-7 3-(2-sec-Butyl-phenoxy)-N-isopropyl-benzamide 
• 65262-68-2 3-(4-Chloro-3,5-dimethyl-phenoxy)-N-isopropyl-benzamide 
• 65262-24-0 N-Isopropyl-3-(2-chlorophenoxy)-benzamid 
• 65262-59-1 3-(4-Chloro-2-methyl-phenoxy)-N-isopropyl-benzamide 
• 65262-77-3 N-Isopropyl-3-(3-chloro-5-methoxyphenoxy)-benzamid 
• 6952-59-6 3-cyanobromobenzene 
• 2415-93-2 1-(3-bromophenyl)-2-methylpropane-1-one 
• 898769-06-7 (3-bromophenyl)(cyclohexyl)methanone 

Relevant academic research and scientific papers

Chemoselective Synthesis of α-Amino-α-cyanophosphonates by Reductive Gem-Cyanation-Phosphonylation of Secondary Amides

A novel approach to α-amino-α-cyanophosphonates has been developed. The method features a Tf2O-mediated reductive geminal cyanation/phosphonylation of secondary amides. Mild reaction conditions, high bond-forming efficiency, inexpensive readily available starting materials, and good to excellent yields with wide functional group compatibility constitute the main advantages of this method. The protocol can be run on a gram scale.

BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases.

1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof

To provide a composition having a steroid C17,20-lyase inhibitory activity and useful as an agent for the prophylaxis or treatment of prostatism and tumors such as breast cancer. A compound represented by the formula: wherein R is a hydrogen atom or a protecting group, R1is a lower alkyl group or a cyclic hydrocarbon group, R2is an aromatic hydrocarbon group optionally having substituents or an aromatic heterocyclic group optionally having substituents, R3is a hydrocarbon group optionally having substituents, a hydroxyl group optionally having substituents, a thiol group optionally having substituents, an amino group optionally having substituents, an acyl group or a halogen atom, and n is an integer of 0 to 4, and a salt thereof have a steroid C17,20-lyase inhibitory activity, and are useful as an agent for the pophylaxis or treatment of prostatism and tumors such as beast cancer and the like.

The halogenation of some benzamides takes place preferentially at the ortho,para positions

The orientation of chlorination and bromination of N,N-disubstituted benzamides in aqueous acetic acid is strongly influenced by the nature of the alkyl groups at the nitrogen atom. With large groups, the halogenation takes place fairly selectively at the ortho/para positions.